<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965051</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0407</org_study_id>
    <nct_id>NCT04965051</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM</brief_title>
  <official_title>A Prospective, Randomized, Open-label, Parallel Group Study to Evaluate Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective, randomized, open-label, parallel group trial, the safety and efficacy of&#xD;
      insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with basal insulin&#xD;
      once or twice daily plus pre-prandial insulin after 16 weeks of treatment in patients with&#xD;
      type 1 diabetes. This trial will enable assessment of the clinically relevant endpoint of a&#xD;
      change in HbA1c and Time in Range (TIR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the current study is to investigate the efficacy and safety of IDegAsp twice&#xD;
      daily compared to basal insulin once or twice daily plus pre-prandial insulin for 16 weeks in&#xD;
      patients with type 1 diabetes mellitus. The primary endpoint in this study is the change from&#xD;
      baseline in HbA1c. Patients with type 1 diabetes who meet the entry criteria are planned for&#xD;
      inclusion in this trial. Approximately 40 patients will be enrolled in the study. Patients&#xD;
      who qualify will be randomized to IDegAsp group or basal plus pre-prandial insulin group.&#xD;
      Duration of treatment includes 2-week screening period, 16-week treatment observation period&#xD;
      and 1-week follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>16 weeks</time_frame>
    <description>the change from baseline in HbA1c after 16 weeks of treatment in all patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time In Range (TIR)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change from baseline in Time in Range (3.9-10mmol/L) after 16 weeks of treatment in all patients (using flash continuous glucose monitoring (FCGM)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to occurrence of treat to target</measure>
    <time_frame>16 weeks</time_frame>
    <description>Fasting glucose on treatment &lt;7mmol/L and non-fasting glucose &lt;10mmol/L, or TIR &gt;70%) (SMBG or FCGM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a treat to target response and without any hypoglycemic episodes</measure>
    <time_frame>16 weeks</time_frame>
    <description>Occurrence of a treat to target response and without any hypoglycemic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D Health Questionnaire</measure>
    <time_frame>16 weeks</time_frame>
    <description>the EQ-5D descriptive system The change from baseline after 16 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 (SF-36)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change from baseline after 16 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change from baseline after 16 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 1 Diabetes Mellitus With Diabetic Gastroparesis</condition>
  <condition>HbA1c</condition>
  <condition>Time in Range</condition>
  <arm_group>
    <arm_group_label>IDegAsp group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDegAsp twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>basal insulin plus pre-prandial insulin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>basal insulin once or twice daily plus pre-prandial insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/insulin aspart (IDegAsp)</intervention_name>
    <description>To evaluate the efficacy and safety of the IDegAsp in T1DM</description>
    <arm_group_label>IDegAsp group</arm_group_label>
    <other_name>Ryzodeg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>basal insulin plus pre-prandial insulin</intervention_name>
    <description>To evaluate the efficacy and safety of basal insulin plus pre-prandial insulin in T1DM</description>
    <arm_group_label>basal insulin plus pre-prandial insulin group</arm_group_label>
    <other_name>Levemir/Lantus/Tresiba plus NovoLog/Humalog/Apidra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 and ≤75 years with type 1 diabetes;&#xD;
&#xD;
          -  Diagnosed as T1DM ≥ 12 months before enrollment in the study;&#xD;
&#xD;
          -  HbA1c ≥ 7.0 to ≤10.0%;&#xD;
&#xD;
          -  Receipt of basal plus pre-prandial insulin and/or oral anti-diabetic agents ≥ 12 weeks&#xD;
             before enrollment in the study;&#xD;
&#xD;
          -  BMI ≤ 35kg / m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any of the following conditions will be excluded:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Severe hypoglycemia within one month;&#xD;
&#xD;
          -  Myocardial infarction, stroke or other severe cardiovascular events within 6 months&#xD;
             prior to informed consent&#xD;
&#xD;
          -  Receipt of Sulfonylureas, Meglitinides derivatives, Thiazolidinediones, Dpp-4&#xD;
             inhibitors or GLP-1 agonists within 3 months prior to informed consent;&#xD;
&#xD;
          -  Current treatment with systemic steroids or immunosuppressive agents, or have&#xD;
             immunologic deficiency disease at time of informed consent&#xD;
&#xD;
          -  Severe mental instability, or alcohol abuse, or drug abuse&#xD;
&#xD;
          -  Cancer within 5 years prior to informed consent&#xD;
&#xD;
          -  Pancreatitis of severe infectious diseases within 1 months prior to informed consent&#xD;
&#xD;
          -  Known hypersensitivity or allergy to the insulin&#xD;
&#xD;
          -  Renal impairment (CKD-EPI eGFR&lt;60ml/min)&#xD;
&#xD;
          -  Impaired hepatic function, defined by serum levels of either ALT (SGPT), AST (SGOT),&#xD;
             or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined&#xD;
&#xD;
          -  Participation in another trial within 2 months prior to informed consent&#xD;
&#xD;
          -  Patients that investigators believe may fail to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuezhong Ren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuezhong Ren, MD</last_name>
    <phone>+86 0571 87783516</phone>
    <email>renyuez@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuezhong Ren</last_name>
      <phone>+8657189713764</phone>
      <email>renyuez@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yuezhong Z Ren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>insulin degludec/insulin aspart</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Time in Range</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

